Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Cencora moves billions of dollars in branded, generic, and specialty drugs—and how much it sets aside for opioid litigation—means combing through dense regulatory documents. Cencora SEC filings explained simply is what most investors search for when a new disclosure lands. Stock Titan solves that problem by turning every freshly posted exhibit, footnote, and schedule into plain-English insights within minutes.
Our platform reads each Cencora annual report 10-K simplified, compares segment margins, and highlights cash-flow drivers hidden in accounting tables. You’ll also receive instant alerts the moment a director files Cencora Form 4 insider transactions real-time. Key features include:
- AI-powered summaries that clarify complex wording and accounting changes
- Real-time push notifications for new 10-K, 10-Q, 8-K, and Cencora insider trading Form 4 transactions
- Side-by-side visuals that streamline Cencora earnings report filing analysis
Whether you’re waiting for the next Cencora quarterly earnings report 10-Q filing, researching Cencora executive stock transactions Form 4, or need Cencora 8-K material events explained after an unexpected acquisition, everything is organized in one place. We even map the pages inside the Cencora proxy statement executive compensation section, so pay packages are only a click away. Stop downloading PDFs; start understanding Cencora SEC documents with AI that surfaces the metrics that matter.
Cencora, Inc. (COR) reported insider activity by President & CEO and Director Robert P. Mauch on 11/07/2025. Two restricted stock unit (RSU) tranches vested and were settled into common stock: 4,215 shares and 4,065 shares (codes M). To cover taxes upon vesting, the filer disposed of 1,735 shares and 1,673 shares at $360.70 per share (code F). After these transactions, Mauch directly beneficially owns 42,812 shares.
Footnotes indicate the RSUs were granted for no consideration and vest in three equal annual installments tied to November 2023–2026 dates.
COR insider Steven Collis filed a Form 144 to sell up to 50,000 common shares through Fidelity Brokerage Services on or about 11/06/2025, to be sold on the NYSE. The filing lists an aggregate market value of $17,762,553.74 and notes 193,877,881 shares outstanding. The shares derive from restricted stock vesting on 11/12/2014, 11/11/2015, 08/07/2016, 11/11/2018, and 11/14/2018. In the past three months, Collis sold 14,579, 31,350, and 31,350 shares for gross proceeds of $4,227,618.42, $9,087,157.00, and $10,251,104.58, respectively.
Cencora, Inc. (COR) filed an 8‑K announcing its earnings release for the fiscal quarter and year ended September 30, 2025, with the news release furnished as Exhibit 99.1. The company also unveiled a new reporting structure to be used beginning in the first quarter of fiscal 2026: U.S. Healthcare Solutions; International Healthcare Solutions; and Other.
U.S. Healthcare Solutions will include U.S. Human Health (excluding legacy U.S. Consulting Services). International Healthcare Solutions will include Alliance Healthcare, Innomar, World Courier, and strategic components of PharmaLex. Other will include businesses for which Cencora has begun to explore strategic alternatives, including MWI Animal Health, Profarma, U.S. Consulting Services, and the other components of PharmaLex. Unaudited revised segment information is furnished as Exhibit 99.2. The company scheduled a conference call and webcast at 8:30 a.m. Eastern time.
Cencora (COR) reported insider equity activity. On 10/31/2025, EVP and Chief Data & Info Officer Pawan Verma settled 8,537 restricted stock units into common stock (transaction code M). To satisfy tax withholding, 4,367 shares were disposed (transaction code F), both at a listed price of $337.81 per share. After these transactions, Verma directly owned 4,184.05 shares.
Cencora (COR) reported an insider equity grant. Director Werner Baumann acquired 108 shares of common stock on 11/01/2025, shown at $337.81 per share, bringing his directly held balance to 3,130 shares.
The filing notes this was a grant of restricted stock units in lieu of a $36,250 quarterly cash retainer under the company’s Non‑Employee Director Compensation Program, with delivery of shares deferred until 02/15/2028.
Cencora (COR) reported an insider transaction by a director. On 11/01/2025, the director acquired 89 shares of common stock at $337.81 per share. Following this transaction, beneficial ownership stands at 3,069 shares, held directly.
The filing notes the shares reflect a grant of restricted stock units received in lieu of a $30,000 quarterly cash retainer under the company’s Non-Employee Director Compensation Program.
Cencora (COR) director Dennis M. Nally reported acquiring 104 shares of common stock on 11/01/2025. The shares were issued in lieu of a $35,000 quarterly cash retainer under the company’s Non-Employee Director Compensation Program, at a reported price of $337.81. Following this transaction, Nally beneficially owns 13,477 shares held directly.
Cencora (COR) CEO and Director Robert P. Mauch reported insider transactions on 10/20/2025. He exercised 3,763 stock options at $86.09 per share and sold 5,097 common shares at $326.80 per share under a Rule 10b5-1 trading plan adopted on 11/15/2024.
Following these transactions, he directly owned 37,940 common shares. The non-qualified stock option had an exercise price of $86.09 and an expiration date of 11/13/2026, with the grant previously vesting in four equal installments.
Form 144 filing: A COR insider filed notice to sell up to 31,350 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $10,251,105.07, on or about October 21, 2025 on the NYSE.
The shares comprise 2,000 acquired via restricted stock vesting on September 30, 2023 and 29,350 tied to options granted on November 13, 2019 to be exercised for cash. Over the past three months, the filer reported sales of 14,578, 14,579, and 31,350 shares for gross proceeds of $4,266,543.26, $4,227,618.42, and $9,087,157.00.
Elizabeth S. Campbell, Executive Vice President and director of Cencora, Inc. (COR), reported a sale of 1,886 shares of Cencora common stock on 10/01/2025 at a price of $313.28 per share. Following the transaction, the reporting person beneficially owned 12,824.141 shares. The Form 4 states the sale was executed under a Rule 10b5-1 trading plan adopted on 12/20/2024. The form is signed by Ms. Campbell on 10/03/2025.
FAQ
What is the current stock price of Cencora (COR)?
What is the market cap of Cencora (COR)?
